Top Markets
#1 ONFA ONFA +217.91%
#2 Resolv wstUSR Resolv wstUSR +198.08%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +36.64%
#6 NKN NKN +34.87%
#7 StakeStone StakeStone +29.44%
#8 BLOCKv BLOCKv +25.50%
#9 KONET KONET +24.76%
#10 OpenVPP OpenVPP +21.34%
Coin of the day
ONFA ONFA
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Classifica tra le azioni #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Prezzo delle azioni
$0.5275
Capitalizzazione di mercato
$1.25M
Variazione (1 giorno)
-3.56%
Variazione (1 anno)
-83.77%
Paese
US
Scambia Ensysce Biosciences, Inc. (ENSC)

Categoria

Healthcare
EPS per Ensysce Biosciences, Inc. (ENSC)
EPS al September 2025 TTM: $-6.37
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Ensysce Biosciences, Inc., l’EPS attuale della società (TTM) è $-6.37. Alla fine del 2023, la società aveva un EPS di $-4.69 un aumento rispetto a rispetto a quello del 2022, che era di $-139.44.
Storico EPS per Ensysce Biosciences, Inc. da 2017 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
2026 (TTM) $-6.37 39.39%
2024 $-4.57 -2.56%
2023 $-4.69 -96.64%
2022 $-139.44 -60.80%
2021 $-355.68 -63,614.29%
2020 $0.56 133.33%
2019 $0.24 -209.09%
2018 $-0.22 4,130.77%
2017 $-0.01 0.00%
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $3.62 -156.86%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $15.47 -342.86%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $43.12 -776.92%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.62 -251.03%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $2.98 -146.78%
AU